Celcuity’s (CELC) “Buy” Rating Reaffirmed at HC Wainwright

Celcuity (NASDAQ:CELC)‘s stock had its “buy” rating restated by analysts at HC Wainwright in a report released on Friday,Benzinga reports. They currently have a $155.00 price target on the stock. HC Wainwright’s price objective indicates a potential upside of 68.46% from the company’s previous close.

CELC has been the topic of several other reports. Macquarie Infrastructure set a $160.00 target price on shares of Celcuity in a research note on Thursday, May 28th. Wall Street Zen lowered shares of Celcuity from a “hold” rating to a “sell” rating in a report on Saturday, April 25th. Leerink Partners set a $155.00 price objective on shares of Celcuity in a research report on Tuesday, June 2nd. Wells Fargo & Company reduced their target price on Celcuity from $183.00 to $166.00 and set an “overweight” rating for the company in a research note on Wednesday, June 3rd. Finally, Needham & Company LLC dropped their price target on Celcuity from $157.00 to $140.00 and set a “buy” rating on the stock in a research note on Friday. Ten analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Celcuity presently has a consensus rating of “Moderate Buy” and a consensus price target of $153.64.

Celcuity Trading Up 6.2%

CELC traded up $5.41 during trading on Friday, hitting $92.01. The company’s stock had a trading volume of 844,880 shares, compared to its average volume of 1,111,195. Celcuity has a twelve month low of $44.42 and a twelve month high of $151.02. The company has a quick ratio of 12.31, a current ratio of 12.31 and a debt-to-equity ratio of 6.04. The stock’s fifty day moving average price is $93.81 and its 200-day moving average price is $108.56. The firm has a market capitalization of $4.49 billion, a P/E ratio of -23.70 and a beta of 0.20.

Celcuity (NASDAQ:CELC) last posted its quarterly earnings results on Thursday, August 13th. The company reported ($1.44) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.16) by ($0.28). The business had revenue of $0.09 million during the quarter, compared to analysts’ expectations of $4.42 million. Analysts anticipate that Celcuity will post -3.76 EPS for the current year.

Institutional Investors Weigh In On Celcuity

Institutional investors and hedge funds have recently made changes to their positions in the business. EverSource Wealth Advisors LLC boosted its stake in Celcuity by 1,329.2% during the 4th quarter. EverSource Wealth Advisors LLC now owns 343 shares of the company’s stock valued at $34,000 after purchasing an additional 319 shares during the last quarter. US Bancorp DE increased its holdings in Celcuity by 25.4% during the 3rd quarter. US Bancorp DE now owns 706 shares of the company’s stock worth $35,000 after purchasing an additional 143 shares in the last quarter. BNP Paribas Financial Markets raised its stake in shares of Celcuity by 78.9% in the second quarter. BNP Paribas Financial Markets now owns 2,647 shares of the company’s stock worth $35,000 after purchasing an additional 1,167 shares during the last quarter. Parallel Advisors LLC purchased a new stake in shares of Celcuity in the first quarter worth approximately $38,000. Finally, Meeder Asset Management Inc. bought a new position in shares of Celcuity in the fourth quarter valued at approximately $42,000. Institutional investors and hedge funds own 63.33% of the company’s stock.

Key Celcuity News

Here are the key news stories impacting Celcuity this week:

• Positive Sentiment: Celcuity’s REVTORPYK (gedatolisib) received FDA approval and was rapidly included in the NCCN Category 1 guidelines, potentially accelerating physician adoption and reducing commercialization risk. Data from the VIKTORIA-1 trial showed strong efficacy and tolerability, supporting expectations that the therapy could become a blockbuster product. Celcuity: REVTORPYK Is Now A Commercial Story
• Positive Sentiment: The company ended the quarter with approximately $754 million in cash, providing funding visibility into 2029 despite increased commercial spending. This liquidity reduces near-term financing risk as Celcuity launches REVTORPYK. Celcuity Second-Quarter 2026 Results
• Neutral Sentiment: Stifel lowered its price target from $175 to $150, while Needham reduced its target from $157 to $140. Both firms maintained Buy ratings, indicating reduced near-term estimates but continued confidence in the long-term opportunity. Needham Lowers Celcuity Price Target
• Negative Sentiment: Second-quarter results highlighted the costs and execution risk of the launch. Celcuity reported a loss of $1.44 per share versus the $1.16 consensus estimate, while revenue of $0.09 million fell far short of the $4.42 million expectation. Analysts subsequently cut their forecasts, and selling, general and administrative expenses are expected to rise as commercialization accelerates. Celcuity Analysts Cut Forecasts

About Celcuity

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.